Duchenne patients get NHS access to PTC’s Translarna
Cost regulators for the NHS in England and Wales have now issued final guidance recommending the use of PTC Therapeutics’ Translarna for patients with Duchenne muscular dystrophy.
Read More
Tag: managed access
NHS England, PTC reach agreement on Duchenne drug
Children in England suffering from a rare form of muscular dystrophy will soon be able to access the only drug licensed for their condition after a ground-breaking agreement was reached between NHS England and PTC Therapeutics.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
